11.19.24 -- A Comprehensive Guide For Supplier Quality Agreements

Discover how a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic.

Reducing risk while maximizing API volume is critical during the fill finish phase of biopharmaceutical manufacturing. To ensure safety and quality, partner with an experienced fill finish provider.

Iwan Bertholjotti, director of commercial bioconjugate development, and Dr. Bernhard Stump, head of bioconjugate development, discuss complexity and uncertainty in the bioconjugates market.

Specializing in oncology, anti-infective and complex formulations, the facility provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

Nanoform CEO Edward Haeggstrom and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

PMs must be technically adept enough to understand a project, but their main role is to ensure it delivers in terms of scope and budget.

An institute researching CRISPR-based genome editing required a custom, highly pure, ultra-low endotoxin nuclease. Learn how Aldevron's expertise helped to demonstrate reduced immune responses compared to using AAV serotype 9 for delivery.

Explore two projects that a focus on improving efficiency and productivity in biopharmaceutical manufacturing while reducing the cost of goods through process intensification.

Poland’s biomanufacturing scene presents an array of benefits to drug sponsors looking to partner globally, including cost-effectiveness, economic stability, and a culture with a strong work ethic.

Providing access to a well-established manufacturing network removes the risk of multiple tech transfers and third parties needed to achieve scale.

This comprehensive guide equips contract manufacturers with the tools to thrive in the ever-evolving life sciences industry. Read how to streamline and optimize your contract manufacturing operations.

Review a CDMO's strategy for overcoming challenges when acquiring new equipment for an Emergency Use Authorization (EUA) project and how leveraging existing resources and collaboration was key.

Allogeneic therapies are gaining popularity due to diversity, scalability, and affordability. A partner with innovative solutions can help streamline the path from discovery to commercialization.

Biopharmaceutical sponsors can minimize to-clinic timelines by using innovative development strategies that trade potentially increased risk for time savings.

Biopharmaceutical tech transfer, critical to the successful development and manufacture of an asset, requires careful planning and evaluation to meet project timelines for scale-up and GMP.